SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotransplant(BTRN)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
1475 39 0 BTRN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1125Would like to see the $6.25 level taken out soon.... "TECHNICAL OPINION - BArthur Radley-11/20/2001
112411/15 JOI. Tolerance, Mixed Chimerism, and Chronic Transplant Arteriopathy1 ,2 keokalani'nui-11/19/2001
1123Monday November 19, 9:27 am Eastern Time Press Release SOURCE: Angiotech PharmacArthur Radley-11/19/2001
1122DeFOREST, Wis., Nov. 19 /PRNewswire/ -- Infigen, Inc. announced today it has sucnigel bates-11/19/2001
1121That's what I said..... I'm impressed by anti-TNF as a stand alone. scaram(o)uche-11/14/2001
1120Rick, >>That said, I always thought that it would take a cocktail of antituck-11/14/2001
1119No, not at all. the dramatic improvements in treatment of RA and other chronic scaram(o)uche-11/14/2001
1118Are we getting to the party toooo late? FDA approves Amgen's rheumatoid arthArthur Radley-11/14/2001
1117Interesting article on RA and of all things...coffee! dailynews.yahoo.comArthur Radley-11/13/2001
1116The following article is about MEDI, but BTRN mentioned in very positive light..Arthur Radley-11/13/2001
1115This is the final portion of Soldier's post from last night...Part 3 by: solArthur Radley-11/13/2001
1114Rebound can be eliminated with ease. BTRN should just use the definition found aknahow-11/13/2001
1113You stated>>>>>>>>>>>>>>MEDI has turneBluegreen-11/13/2001
1112part 2 by: soldier30 11/12/01 09:05 pm Msg: 1301 of 1302 ú Abstracts froArthur Radley-11/12/2001
1111Lazard-part 1 by: soldier30 11/12/01 09:05 pm Msg: 1300 of 1302 09:11am EST 9Arthur Radley-11/12/2001
1110part 8 by: soldier30 11/12/01 09:01 pm Msg: 1299 of 1302 Gambro BCT and BioTrArthur Radley-11/12/2001
1109part 7 by: soldier30 11/12/01 09:00 pm Msg: 1298 of 1302 In our view, the iniArthur Radley-11/12/2001
1108part 6 by: soldier30 11/12/01 08:59 pm Msg: 1297 of 1302 Abstract number 1753Arthur Radley-11/12/2001
1107part 5 by: soldier30 11/12/01 08:57 pm Msg: 1296 of 1302 09:15am EST 9-Nov-01Arthur Radley-11/12/2001
1106part 4 by: soldier30 11/12/01 08:53 pm Msg: 1295 of 1302 Abstract number 3554Arthur Radley-11/12/2001
1105part 3 by: soldier30 11/12/01 08:53 pm Msg: 1294 of 1302 Phase III trials. ImArthur Radley-11/12/2001
1104part 2 by: soldier30 11/12/01 08:50 pm Msg: 1293 of 1302 Impressive MEDI-507 Arthur Radley-11/12/2001
1103Soldier has been kind enough to post the following information over on Yahoo!..IArthur Radley-11/12/2001
1102Any comments on this ...http://biz.yahoo.com/prnews/011112/nym128_1.html .. and Arthur Radley-11/12/2001
1101Potential delay for stem cell research.....http://dailynews.yahoo.com/h/nm/20011Arthur Radley-11/12/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News